Document Type
Article
Journal Title
Nicotine & Tobacco Research
Publication Date
2012
Volume
14
Abstract
INTRODUCTION: Current smoking cessation guidelines recommend setting a quit date prior to starting pharmacotherapy. However, providing flexibility in the date of quitting may be more acceptable to some smokers. The objective of this study was to compare varenicline 1 mg twice daily (b.i.d.) with placebo in subjects using a flexible quit date paradigm after starting medication.
METHODS: In this double-blind, randomized, placebo-controlled international study, smokers of ≥10 cigarettes/day, aged 18-75 years, and who were motivated to quit were randomized (3:1) to receive varenicline 1 mg b.i.d. or placebo for 12 weeks. Subjects were followed up through Week 24. Subjects were instructed to quit between Days 8 and 35 after starting medication. The primary endpoint was carbon monoxide-confirmed continuous abstinence during Weeks 9-12, and a key secondary endpoint was continuous abstinence during Weeks 9-24.
RESULTS: Overall, 493 subjects were randomized to varenicline and 166 to placebo. Continuous abstinence was higher for varenicline than for placebo subjects at the end of treatment (Weeks 9-12: 53.1% vs. 19.3%; odds ratio [OR] 5.9; 95% CI, 3.7-9.4; p < .0001) and through 24 weeks follow-up (Weeks 9-24: 34.7% vs. 12.7%; OR 4.4; 95% CI, 2.6-7.5; p < .0001). Serious adverse events occurred in 1.2% varenicline (none were psychiatric) and 0.6% placebo subjects. Fewer varenicline than placebo subjects reported depression-related adverse events (2.3% vs. 6.7%, respectively).
CONCLUSIONS: Varenicline 1 mg b.i.d. using a flexible quit date paradigm had similar efficacy and safety compared with previous fixed quit date studies.
MeSH Headings
Adult, Benzazepines, Drug Administration Schedule, Humans, Middle Aged, Nicotinic Agonists, Quinoxalines, Smoking Cessation, Tobacco Use Cessation Devices, Varenicline
DOI Link
ISSN
1469-994X
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 3.0 License
Recommended Citation
Rennard, Stephen I.; Hughes, John; Cinciripini, Paul M.; Kralikova, Eva; Raupach, Tobias; Arteaga, Carmen; St Aubin, Lisa B.; Russ, Cristina; and the Flexible Quit Date Study Group, "A Randomized Placebo-Controlled Trial of Varenicline for Smoking Cessation Allowing Flexible Quit Dates" (2012). Journal Articles: Pulmonary & Critical Care Med. 85.
https://digitalcommons.unmc.edu/com_pulm_articles/85
Included in
Allergy and Immunology Commons, Critical Care Commons, Respiratory System Commons, Respiratory Tract Diseases Commons